Background and significance {#s1}
===========================

Errors in the recording of prescription medication histories are distressingly common in the hospital setting, occurring in upwards of 50--70% of admitted patients.[@R1] Over one quarter of these errors are attributable to incomplete medication histories obtained at the time of admission.[@R4] In many cases, medication discrepancies lead to interrupted or inappropriate drug therapy during and after hospitalization, [@R5] and are an important contributor to adverse drug events among hospitalized and recently discharged patients.[@R3] [@R6] Following hospital discharge, the perpetuation of these errors may result in unintended disruptions in essential treatment, drug interactions or therapeutic duplication---all of which have the potential to cause significant clinical harm and result in additional healthcare costs.[@R7] Indeed, a recent study suggests that there may be a 10% increase in adverse drug events among patients whose medication was unintentionally disrupted by a hospital stay.[@R6]

Although research in this area remains limited, some studies have shown significant discrepancies between medication lists generated during emergency department (ED) triage and those later verified by a pharmacist.[@R1] [@R7] [@R8] The most common example is the omission of medications taken at home;[@R2] [@R7] over 59% of medication histories recorded by physicians differ from those collected by pharmacy staff,[@R2] and although pharmacists are more effective in obtaining an accurate medication history, they are not available for all patient encounters.[@R9] While computerized provider order entry systems are effective in minimizing the risk associated with prescribing errors, they cannot detect home medication use without linkage to a community pharmacy database.[@R7] Better methods of obtaining the complete community drug list for each patient upon hospital admission would help to avoid preventable adverse drug events and increase the utility of community pharmacy systems in improving patient safety. The development of health information exchanges (HIE) in the USA and the pan-Canadian electronic health record in Canada are examples of technological infrastructures that could be used to provide access to community pharmacy records.[@R10] [@R11] What remains unclear is whether access to community-based pharmacy records will provide substantially more information about prescription drug use than conventional medication histories.

Two recent studies, one conducted in Denmark and the other in the USA, set out to evaluate the magnitude of discrepancy between these two sources of information; however, their results were conflicting. In the Danish study, 27% of medications documented in electronic pharmacy records were not reported by patients on admission to an acute medical emergency ward, whereas only 6% of medications reported by patients were omitted from pharmacy records.[@R12] In contrast, in the American study, 30% of medications reported by patients were not included in an insurance claims database, possibly because unlike pharmacy records, which record all prescriptions dispensed, insurance claims only include those drugs that are covered.[@R13] Neither of these studies identified the characteristics of patients at risk of having discrepancies in their medication histories. These data are needed to evaluate the extent to which investment in and maintenance of HIE will produce clinical value for patients.

Objective {#s2}
=========

The purpose of this study was to determine the extent to which community medication histories documented in the ED differed from records of dispensed medications provided by community pharmacies, and the patient and drug-related predictors of discrepancies that could be used to identify higher risk groups.

Materials and methods {#s3}
=====================

Setting {#s3a}
-------

This study took place at two teaching hospitals in Quebec, Canada, where all residents have provincial medical insurance, and approximately 50% of the population is covered by public drug insurance. Claims records for all dispensed medications from Quebec pharmacies and medical services from fee-for-service physicians are maintained at the Régie de l\'Assurance Maladie du Quebec (RAMQ) and can be linked using a unique lifetime identifier to create a longitudinal health record for each provincial resident.

Study design and participants {#s3b}
-----------------------------

A prospective cohort study was conducted. Individuals who were seen in the ED at the Royal Victoria Hospital and the Montreal General Hospital between 21 May and 27 August 2008, who were 18 years of age or older, reported that they took at least one prescription medication and who had public drug insurance were asked to participate. Research assistants assessed eligibility and sought patient consent. The McGill University Health Centre\'s ethics committee, the RAMQ, and the provincial privacy commission approved the study.

Data collection and retrieval {#s3c}
-----------------------------

For each consenting patient, two different community drug lists were retrieved: one that contained the drug list recorded by the triage nurse and ED staff in the patient\'s paper-based medical chart at the time of their ED visit, and another obtained from the community pharmacy records of dispensed medications recorded in the administrative databases of the RAMQ. For patients with multiple ED visits during the study period, only information pertaining to their first visit was collected from the ED chart and the community pharmacy records.

### Chart retrieval {#s3c1}

Trained research assistants reviewed all prescription drugs recorded in the ED section of the patient\'s hospital chart and entered the community drug list (drug name, strength, form) documented at the time of the visit into an electronic database. To minimize data entry errors, the database auto-generated a list of possible drug names from the first three typed letters; once the drug was selected, the strength and form was selected from a drop-down list, or entered in a free text field if the correct option was not available. If a drug name, strength, or form was missing or illegible, this information was also recorded in the database. All drugs, both prescription and over the counter, were coded by drug identification number, when possible, and/or by the generic drug code (ie, by drug ingredient regardless of manufacturer or format) using a proprietorial classification system (Vigilance Santé).[@R14] The number of illegible drugs was recorded for each patient, when applicable.

### Provincial insurer (RAMQ) medication list retrieval from Quebec pharmacies {#s3c2}

For each consenting patient, data on all prescription drugs dispensed from Quebec pharmacies in the year before the ED visit date were retrieved from the RAMQ. Data included medication drug identification number, strength, format, quantity dispensed, the duration of the prescription, and encrypted identifiers for each of the patients, prescribing physician, and dispensing pharmacy. Dispensed drugs were grouped by generic code and those with an active prescription within the 2 months before the ED visit date were classified as current community medications. Patients using medications for chronic conditions may miss 20% of doses (a mean compliance of 80%), and thus a window of 2 months back from the ED visit date was used to identify current medication.

Main outcome {#s3d}
------------

The primary outcome was a discrepancy between community medications that were documented in the ED chart compared to dispensed medication records from the RAMQ databases. A discrepancy was defined as the absence of a drug with the same generic drug code in either the ED or RAMQ drug lists. All illegible drug entries in the ED chart were excluded.

Predictors of discrepancies {#s3e}
---------------------------

Potential patient and drug-related predictors of medication list discrepancies were measured with the aim of identifying subsets of patients who may be at greater risk of an incomplete community medication history. As many jurisdictions do not have access to records of dispensed medications, we assessed patient characteristics that were associated with a greater number of medications in pharmacy-recorded claims relative to the ED chart. Using a combination of medical chart and administrative data, we measured patient age and sex, health conditions that would create potential communication barriers,[@R15] as well as the number and therapeutic classes of medications as these factors may influence patient recall and communication. Using administrative data we measured the frequency of ED visits, and hospitalization in the past year, as well as the number of pharmacies and physicians involved in prescribing and dispensing as these factors create challenges in the continuity of care. Published algorithms were employed to measure patient and healthcare utilization characteristics.[@R16] Over-the-counter drugs were excluded, as they are not recorded in the pharmacy records.

Statistical analysis {#s3f}
--------------------

Descriptive statistics were used to characterize the cohort, and to examine the frequency of discrepancies between the ED and Quebec pharmacy dispensing records for prescription drugs, by class and most frequent generic drugs. Multivariate logistic regression was used to estimate the association between patient demographics, health conditions, and healthcare utilization, as well as the likelihood of having more prescribed drugs listed in the pharmacy records than the ED chart. We estimated both the univariate and multivariate associations for each variable. To avoid multi-collinearity, we selected only one variable when multiple variables measuring the same concept were used (eg, number and types of drugs). SAS V.9.2 was used for all analyses.

Results {#s4}
=======

Overall, 613 patients met the eligibility criteria and were enrolled in the study. The mean patient age was 63.1 years, 59.2% were women, and 32.6% had health conditions that may have created potential communication barriers ([table 1](#AMIAJNL2013001704TB1){ref-type="table"}). In the year before the ED visit, 45.7% of patients had four or more prescribing physicians, and 7.5% had four or more pharmacies.

###### 

Demographic and healthcare utilization characteristics of the 613 patients in the study population in the year before the ED visit

  Demographic characteristics                        Mean   SD
  -------------------------------------------------- ------ ------
  Patient age (years)                                63.1   18.8
                                                     N      \%
   \<50 years                                        150    24.5
   50--70 years                                      197    32.1
   \>70 years                                        266    43.4
  Sex                                                       
   Female                                            363    59.2
   Male                                              250    40.8
  Health conditions with communication barriers             
  Any condition                                      200    32.6
   Psychiatric disorder\*                            183    29.9
   Social distancing problem†                        32     5.2
   Physical communication problems‡                  3      0.5
  Healthcare utilization in past year                       
  No of ED visits in past year                              
   No visits                                         307    50.1
   1 Visit                                           141    23.0
   2--3 Visits                                       104    17.0
   ≥4 Visits                                         61     10.0
  No of hospitalizations in past year                       
   No hospitalizations                               412    67.2
   1 Hospitalization                                 116    18.9
   ≥2 Hospitalizations                               85     13.9
  Continuity of medication management in past year          
  No of prescribing physicians in past year                 
   No information on prescribers                     35     5.7
   1 Prescriber                                      84     13.7
   2--3 Prescribers                                  214    34.9
   ≥4 Prescribers                                    280    45.7
  No of pharmacies in past year                             
   No information on pharmacies                      33     4.5
   1 Pharmacy                                        327    53.3
   2--3 Pharmacies                                   207    33.8
   ≥4 Pharmacies                                     46     7.5

\*Including diagnoses for depression, anxiety and adjustment disorders, schizophrenia and other psychotic disorders, mood disorder including bipolar and personality disorder.

†Includes alcoholism, drug abuse and homelessness.

‡Includes documented communication difficulties, blindness and deafness.

ED, emergency department.

Approximately one quarter (26.1%) of patients had more than 12 active prescription drugs documented at the ED visit, either in the hospital chart or through the pharmacy records; 57.3% used at least one over-the-counter medication, and 14.5% had at least one illegible drug in the ED chart ([table 2](#AMIAJNL2013001704TB2){ref-type="table"}).

###### 

Characteristics of prescribed and OTC medication use at ED visit and discrepancies between ED and pharmacy record sources at the time of the ED visit

  No of prescribed drugs (either ED or pharmacy source)            N     \%
  ---------------------------------------------------------------- ----- ------
   0 Drugs (only OTC)                                              8     1.3
   1 Drug                                                          36    5.9
   2--6 Drugs                                                      220   35.9
   7--12 Drugs                                                     189   30.8
   \>12 Drugs                                                      160   26.1
  Patients with ≥1 OTC medication                                  351   57.3
  Patients with ≥1 illegible drug in the ED chart                  89    14.5
  Drug use by therapy class                                              
   Central nervous system agents                                   360   58.7
   Cardiovascular drugs                                            363   59.2
   Hormones and synthetic substitutes                              282   46.0
   Blood formation, coagulation and thrombosis                     218   35.5
   Gastrointestinal drugs                                          211   34.4
   Electrolytic, caloric and water balance                         237   38.9
   Anti-infective agents                                           162   26.4
   Autonomic drugs                                                 161   26.3
   Eye, ear, nose and throat preparations                          93    15.7
   Other                                                           273   44.5
  No of prescribing physicians                                           
   No information on prescribers                                   45    7.3
   1 Prescriber                                                    189   30.8
   2--3 Prescribers                                                265   43.2
   ≥4 Prescribers                                                  114   18.6
  No of pharmacies                                                       
   No information on pharmacies                                    45    7.3
   1 Pharmacy                                                      444   72.4
   2--3 Pharmacies                                                 114   18.6
   ≥4 Pharmacies                                                   10    1.6
  Differences between pharmacy records and ED chart                      
  Pharmacy records document more prescribed drugs than ED chart    463   75.5
   1 More drug                                                     122   19.9
   2--4 More drugs                                                 219   35.7
   ≥5 Drugs                                                        122   19.9
  ED chart documents more prescribed drugs than pharmacy records   73    11.9
   1 More drug                                                     31    5.0
   2--4 More drugs                                                 25    4.1
   ≥5 Drugs                                                        17    2.8

ED, emergency department; OTC, over-the-counter.

The most prevalent over-the-counter medications were acetaminophen, acetylsalicylic acid, multivitamins, and calcium ([table 3](#AMIAJNL2013001704TB3){ref-type="table"}). For prescribed medications, 30.8% of patients had a single prescribing physician, and 72.4% had a single dispensing pharmacy. Cardiovascular drugs, central nervous system agents, hormones and synthetic substitutes were the most prevalent therapies Pharmacy records documented more active drugs than the ED chart in 75.5% of patients, and in 11.9%, the ED chart listed more medications.

###### 

Frequency distribution of OTC drugs documented in the ED chart by therapeutic class and most frequently used drugs

  Therapeutic class                             N     \% of all OTC drugs   \% of patients using drug
  --------------------------------------------- ----- --------------------- ---------------------------
  Central nervous system agents                 175   24.8                  28.5
   Acetaminophen                                85    12.1                  13.9
   ASA                                          80    11.3                  13.1
   Ibuprofen                                    9     1.3                   1.5
  Electrolytic, caloric and water balance       118   16.7                  19.2
   Calcium carbonate+vitamin D                  35    5.0                   5.7
   Calcium carbonate                            28    4.0                   4.6
   Calcium citrate                              28    4.0                   4.6
  Blood formation, coagulation and thrombosis   111   15.7                  18.1
   ASA antiplatelet                             85    12.1                  13.9
   Ferrous sulfate                              12    1.7                   2.0
   Iron-chelated                                7     1.0                   1.1
  Vitamins                                      95    13.5                  15.5
   Multivitamins                                39    5.5                   6.4
   Vitamin D3                                   18    2.6                   2.9
   Vitamin D                                    12    1.1                   2.0
  Gastrointestinal drugs                        101   14.3                  16.5
   Docusate sodium                              38    5.4                   6.2
   Sennosides A--B                              21    3.0                   3.4
   Dimenhydrinate                               9     1.3                   1.5
  Skin and mucous membrane agents               27    3.8                   4.4
   Petrolatum-white                             8     1.1                   1.3
   Gramicidin+PO Lymyxin B                      3     0.4                   0.5
   Clotrimazole                                 3     0.4                   0.5
  Other\*                                       87    11.4                  14.1
   Quinine sulfate                              9     1.3                   1.5
   Potassium iodide+ammonium chloride           7     1.0                   1.1
   Products natural miscellaneous               6     0.9                   1.0

\*Other: Miscellaneous therapeutic agents, antihistamine drugs, respiratory tract agents, diagnostic agents, devices, anti-infective agents, autonomic drugs, eye, ear, nose and throat preparations.

ASA, acetylsalicylic acid; ED, emergency department; OTC, over-the-counter.

There was concordance between the ED chart and pharmacy records for 45.2% of medications, 41.5% were only identified in the pharmacy records, and 13.4% were only in the ED chart. Concordance was highest for anticoagulants (64.6%), cardiovascular drugs (61.4%), and diuretics (56.2%) ([table 4](#AMIAJNL2013001704TB4){ref-type="table"}).

###### 

Discrepancies in prescribed drugs between pharmacy records\* and the ED chart by therapeutic class

  Therapeutic class†                            Total   ED only (n, %)   Pharmacy only (n, %)   Documented in both (n, %)
  --------------------------------------------- ------- ---------------- ---------------------- ---------------------------
  Cardiovascular drugs                          903     113 (12.5)       236 (26.1)             554 (61.4)
   Atorvastatin                                 120     13 (10.8)        27 (22.5)              80 (66.7)
   Amlodipine                                   80      3 (3.8)          15 (18.8)              62 (75.5)
   Metoprolol                                   69      8 (11.6)         12 (17.4)              49 (71.0)
  Central nervous system agents                 716     121 (16.9)       331 (46.2)             264 (36.9)
   Lorazepam                                    64      8 (12.5)         27 (42.2)              29 (45.3)
   Naproxen                                     42      6 (14.3)         28 (66.7)              8 (19.0)
   Codeine+acetaminophen                        40      6 (15.0)         30 (75.0)              4 (10.0)
  Hormones and synthetic substitutes            408     47 (11.5)        134 (32.8)             227 (55.6)
   Levothyroxine                                97      5 (5.2)          18 (18.6)              74 (76.3)
   Metformin                                    87      7 (8.0)          9 (10.3)               71 (81.6)
   Prednisone                                   38      2 (5.3)          20 (52.6)              16 (42.1)
  Blood formation, coagulation and thrombosis   96      15 (15.6)        19 (19.8)              62 (64.6)
   Warfarin                                     48      9 (18.8)         4 (8.3)                35 (72.9)
   Clopidogrel                                  24      1 (4.2)          7 (29.2)               16 (66.7)
   Dalteparin                                   4       1 (25.0)         2 (50.0)               1 (25.0)
  Gastrointestinal drugs                        232     23 (9.9)         102 (44.0)             107 (46.1)
   Pantoprazole                                 108     13 (12.0)        43 (39.8)              52 (48.1)
   Esomeprazole                                 33      5 (15.2)         14 (42.4)              14 (42.4)
   Omeprazole                                   29      0                13 (44.8)              16 (55.2)
  Electrolytic, caloric and water balance       169     17 (10.1)        57 (33.7)              95 (56.2)
   Furosemide                                   65      8 (12.3)         17 (26.6)              40 (61.5)
   Hydrochlorothiazide                          65      8 (12.3)         20 (30.8)              37 (56.9)
   Indapamide                                   16      1 (6.3)          7 (43.8)               8 (50.0)
  Anti-infective agents                         239     24 (10.0)        180 (75.3)             35 (14.6)
   Ciprofloxacin                                36      3 (8.3)          28 (77.8)              5 (13.9)
   Amoxicillin                                  25      2 (8.0)          20 (80.0)              3 (12.0)
   Azithromycin                                 18      2 (11.1)         16 (88.9)              0
  Autonomic drugs                               249     49 (18.7)        108 (43.4)             92 (36.9)
   Salbutamol                                   74      19 (25.7)        37 (50.0)              18 (24.3)
   Tamsulosin                                   31      5 (16.1)         10 (32.3)              16 (51.6)
   Tiotropium                                   26      4 (15.4)         11 (42.3)              11 (42.3)
  Eye, ear, nose and throat preparations        172     25 (14.5)        118 (68.6)             29 (16.9)
   Fluticasone                                  53      8 (15.1)         36 (67.9)              9 (17.0)
   Latanoprost                                  16      2 (12.5)         10 (62.5)              4 (25.0)
   Mometasone                                   16      3 (18.8)         12 (75.0)              1 (6.3)
  Skin and mucous membrane agents               89      10 (11.2)        72 (80.9)              7 (7.9)
   Betamethasone valerate                       8       1 (12.5)         7 (87.5)               0
   Mometasone furoate                           8       1 (12.5)         7 (87.5)               0
   Fluocinonide                                 6       1 (16.7)         5 (83.3)               0
  Other‡                                        208     22 (10.6)        86 (41.3)              100 (48.1)
   Alendronate                                  31      2 (6.5)          12 (38.7)              17 (54.8)
   Risedronate                                  30      3 (10.0)         11 (36.7)              16 (53.3)
   Allopurinol                                  18      1 (5.6)          5 (27.8)               12 (66.7)
  Overall                                       3481    466 (13.4)       1443 (41.5)            1572 (45.2)

\*Active prescribed drugs in the 2 months before the ED visit.

†Includes the three most common drugs in each therapeutic class.

‡Including respiratory tract agents, devices, antineoplastic agents, miscellaneous therapeutic agents, diagnostic agents, vitamins, smooth and muscle relaxants, heavy metal antagonists.

ED, emergency department.

Drugs that are taken episodically were more frequently recorded in pharmacy records only ([table 4](#AMIAJNL2013001704TB4){ref-type="table"}). For example, 80.9% of skin agents, 75.3% of anti-infective drugs, 68.6% of eye, ear nose and throat medications, 46.2% of central nervous system agents, 44.0% of gastrointestinal drugs, and 43.4% of autonomic drugs, such as bronchodilators, were only recorded in pharmacy records. In the case of anti-infective drugs, 91% of patients who used anti-infective agents had a prescription end-date that preceded the ED visit; however, 34% of patients were prescribed multiple different anti-infective agents in the past 2 months. Of interest, 9.9% (gastrointestinal drugs) to 18.7% (autonomic drugs) of drugs were listed in the ED chart but were not found in pharmacy records of dispensed medications, at least in the 2 months before the ED visit.

The likelihood of having more drugs documented in pharmacy records than the ED chart was associated with the number of prescribed drugs, and the number of pharmacies, but not age, sex, hospitalizations or communication problems. ([table 5](#AMIAJNL2013001704TB5){ref-type="table"}). Patients with more frequent ED visits were more likely to have discrepancies in bivariate analysis, but these trends were largely explained by the number of medications and healthcare use and were not significant in multivariate analysis.

###### 

Factors associated with discrepancies: more drugs in pharmacy records than documented in the ED chart

  Factors                            More drugs pharmacy records   Bivariate analysis      Multivariate analysis                            
  ---------------------------------- ----------------------------- ----------------------- ----------------------- ------------------------ ---------
  Patient age (years)                                                                                                                       
   \<50                              111 (23.9)                    Ref.                                            Ref.                     
   50--70                            149 (32.0)                    1.09 (0.67 to 1.78)     0.72                    0.875 (0.504 to 1.518)   0.64
   \>70                              205 (44.1)                    1.18 (0.75 to 1.88)     0.47                    0.814 (0.470 to 1.412)   0.46
  Gender                                                                                                                                    
   Female                            273 (58.7)                    Ref.                                                                     
   Male                              192 (41.3)                    1.09 (0.75 to 1.59)     0.66                    1.00 (0.67 to 1.49)      0.99
  Communication barrier              158 (34.0)                    1.29 (0.86 to 1.94)     0.22                    1.08 (0.69 to 1.67)      0.75
  No of prescribed drugs                                                                                                                    
   1 Dug                             18 (3.9)                      0.66 (0.31 to 1.42)     0.29                    0.74 (0.33 to 1.68)      0.47
   2--6 Drugs                        137 (29.5)                    Ref.                                            Ref.                     
   7--12 Drugs                       121 (26.0)                    1.86 (1.16 to 3.00)     0.01                    1.99 (1.21 to 3.29)      0.007
   ≥12 Drugs                         166 (33.3)                    2.92 (1.80 to 4.76)     \<.0001                 2.92 (1.71 to 4.97)      \<.0001
  Therapeutic class†                                                                                                                        
   Cardiovascular                    286 (61.5)                    Ref.                                                                     
   Central nervous system            289 (62.2)                    1.64 (1.09 to 2.46)     0.01                                             
   Hormones/synthetic subs.          222 (47.7)                    1.11 (0.73 to 1.67)     0.63                                             
   Blood, coag/thrombosis            192 (41.3)                    2.96 (1.79 to 4.89)     \<.0001                                          
   Gastrointestinal                  181 (38.9)                    1.69 (1.05 to 2.71)     \<.0001                                          
   Electrolytic, caloric and water   196 (42.2)                    1.12 (0.71 to 1.76)     0.64                                             
   Anti-infectives                   145 (31.2)                    3.49 (1.99 to 6.12)     \<0.001                                          
   Autonomic                         128 (27.5)                    0.72 (0.44 to 1.19)     0.20                                             
   Eye, ear, nose and throat         77 (16.6)                     0.96 (0.51 to 1.79)     0.89                                             
   Other                             236 (50.8)                    2.46 (1.57 to 3.86)     \<.0001                                          
  ED visits in past year                                                                                                                    
   No visits                         218 (46.9)                    Ref.                                            Ref.                     
   1 Visit                           107 (23.0)                    1.28 (0.81 to 2.02)     0.30                    1.14 (0.70 to 1.84)      0.61
   2--3 Visits                       85 (18.3)                     1.80 (1.03 to 3.12)     0.04                    1.58 (0.86 to 2.89)      0.14
   ≥4 Visits                         55 (11.8)                     3.50 (1.49 to 8.23)     0.004                   2.33 (0.91 to 5.96)      0.08
  Hospitalizations in past year                                                                                                             
   No hospitalization                304 (65.4)                    Ref.                                            Ref.                     
   ≥1 Hospitalization                161 (34.6)                    1.42 (0.95 to 2.14)     0.09                    0.93 (0.58 to 1.50)      0.76
  Current pharmacies                                                                                                                        
   1 Pharmacy                        352 (75.7)                    Ref.                                            Ref.                     
   ≥2 Pharmacies                     113 (24.3)                    3.85 (2.03 to 7.30)     \<.0001                 3.45 (1.80 to 6.59)      0.0002
  Current prescribing MD\*                                                                                                                  
   1 Prescriber                      128 (27.5)                    Ref.                                                                     
   2--3 Prescribers                  228 (49.0)                    5.05 (3.28 to 7.77)     \<.0001                                          
   ≥4 Prescribers                    109 (23.4)                    16.50 (6.72 to 40.50)   \<.0001                                          
  Pharmacies past year†                                                                                                                     
   1 Pharmacy                        253 (54.4)                    Ref.                                                                     
   2--3 Pharmacies                   172 (37.0)                    2.06 (1.35 to 3.16)     \<.0001                                          
   ≥4 Pharmacies                     40 (8.6)                      2.64 (1.11 to 6.23)     0.03                                             
  Prescribing MD past year\*                                                                                                                
   1 Prescriber                      55 (11.8)                     Ref.                                                                     
   2--3 Prescribers                  161 (34.6)                    3.50 (2.18 to 5.64)     \<.0001                                          
   ≥4 Prescribers                    249 (53.5)                    9.21 (5.45 to 15.44)    \<.0001                                          

\*Number of prescribing physicians and number of drugs was strongly correlated (r=0.54) so only number of drugs was included in the model.

†Therapeutic drug classes and number of drugs was correlated so only number of drugs was included in the multivariate model. We selected the utilization variable for number of pharmacies that was most strongly associated with the outcome.

ED, emergency department; MD, physician.

Patients using more than 12 drugs were almost three times more likely (OR 2.92, 95% CI 1.71 to 4.97) to have drugs documented in pharmacy records that were not noted in the ED chart. Compared to cardiovascular drugs, anti-infective drugs, blood formation, coagulation and thrombosis drugs, gastrointestinal drugs, and central nervous system drugs were more likely to be documented only in pharmacy records and not the ED chart. The number of prescribing physicians, both in the past year and for current medications, was associated with the likelihood of having more drugs documented in pharmacy records. However, the number of prescribing physicians was also strongly correlated with the number of drugs (r=0.54, p\<.0001), so only the number of drugs was included in the multivariate models. Using more than one pharmacy, both in the past year and for current medication, was associated with more than a threefold increase (OR 3.45, 95% CI 1.80 to 6.59) in the risk of having more medications listed in pharmacy records, even after adjusting for the number of current medications.

Discussion {#s5}
==========

This study provides insight into the potential value of accessing information electronically from community pharmacy medication records at the time of an ED visit. Pharmacy records identified 41.5% more prescribed medications that were not noted in the ED chart. More vulnerable patients, that is, those with many medications, many prescribing physicians, and multiple ED visits were more likely to have omissions in their ED record of current medications. Although having potential communication problems did not turn out to be a significant predictor of medication discrepancies, patients who were unconscious or agitated would have been less likely to be enrolled in this study because of known consent biases,[@R20] and thus we probably underestimated these effects. We found that omissions were more common for some groups of medications than others, particularly for therapeutic classes of drugs that may be taken episodically to control symptoms: anxiolytics, analgesics, gastrointestinal drugs, and asthma medications. The clinical significance of discontinuing these medications, even when intended, is substantial as discontinuation results in an adverse event rate of 14.3% (gastrointestinal drugs) to 29.7% (anxiolytics) in older people.[@R21] These groups of medications are more likely to be 'forgotten' by patients in self-reported surveys of medication use[@R7] [@R22] and ED medication histories[@R2] when compared to home-based assessment of medicine cabinets,[@R25] [@R26] and pharmacist review.[@R2] Although most cardiovascular and anticoagulant medications were documented in both the ED chart and pharmacy records, 29.2% of patients prescribed clopidogrel, and 8.3% of those prescribed warfarin had these medications only documented in pharmacy records. Although ED staff may selectively solicit information about these medications (particularly anticoagulants) as these drugs are frequently involved in adverse drug events,[@R27] there is clearly benefit in obtaining pharmacy records for patients on these medications.

Although pharmacy records of dispensed medications do not reflect actual usage, they can provide a clinically useful proxy. Several validation studies have shown that medication possession ratios calculated from pharmacy records are predictive of various measures of disease control such as blood pressure, glycosylated hemoglobin levels, and asthma exacerbation.[@R31] There is also excellent agreement between dispensing records and the use of antihypertensive drugs.[@R31] [@R32] [@R36] [@R37] Moreover, if access to dispensed medications records from community pharmacies is automated, there is considerable potential to improve efficiencies for hospital-based pharmacists in documenting the best medication history,[@R38] [@R39] as the average time spent per patient for this task can range from 13 to 90 min.[@R7] [@R40] [@R41]

To optimize the utility of access to computerized community-based pharmacy records, a few issues need to be addressed. First, a decision needs to be made about the time window that will be used to retrieve data. In this study, we included medications in the 2 months before the ED visit. For patients with poor compliance, we found that we could only pick up medications that were only documented in the ED chart if we looked back 12 months before the ED visit. In contrast, a shorter time window may be more appropriate to exclude short-term treatments such as antibiotics, which were likely to be 'over-reported' as current medications, because 91% had an end-date that preceded the ED visit. However, of interest was the fact that we found that 34% of patients were taking more than one anti-infective drug in the past 2 months. This information could be relevant to ED staff in detecting adverse anti-infective drug events or in avoiding previous failed treatment choices. To accommodate these issues, the window for retrieving medications for clinical use needs to be adjustable, allowing the user to conduct reviews by time period, therapy class, population, and insurance cost-sharing policies that affect compliance. Mean prescription duration is also an important factor to consider, as in some jurisdictions 3-month durations (versus 1 month in Quebec) are the norm, and thus a longer retrieval window will be needed.

Our results demonstrate the potential value in having access to community-based pharmacy records through infrastructures such as HIE, because they provide more information about prescription drug use compared to conventional medication histories. However, the cost of integrating and sustaining electronic access to these records would need to be justified by either a reduction in professional time for medication history-taking (which is a substantial barrier to the medication reconciliation process), and/or in preventable adverse drug events. To date, cost--benefit models of HIE have been largely theoretical, based on economic modeling of assumed benefits and cost-savings.[@R42] [@R43] The lack of empirical evidence of the sources and types of cost saving may be one reason why most regional HIE in the USA have not established viable business models for financial sustainability.[@R44] A recent evaluation of HIE in ED care in Tennessee is among one of the first studies to provide evidence that HIE implementation can reduce hospitalizations, and in some cases, can reduce diagnostic and laboratory test ordering, producing an annual cost savings of US\$1.07 million.[@R45]

Greater efficiencies and cost savings in professional time could be gained with automated access to pharmacy records if patients were provided with an opportunity to verify the medications they were taking. An interesting approach was evaluated in the Veteran\'s hospital system. Kiosks were available in the ED for patients to retrieve and verify medications they were actually taking based on records of dispensed prescriptions.[@R46] A majority of the ED staff agreed that the tool was effective; however, the overwhelming volume of information made identifying discrepancies in the medication lists difficult, and some providers felt that it increased their workload. Despite these shortcomings, the kiosk was successfully integrated in the ED workflow and even patients with poor computer skills were able to use it. Similar features could be included in personal health records and patient portals that are linked to community pharmacy information systems, and this may be a fruitful area for future research.

Limitations that need to be considered are that the study was based in two teaching hospitals where electronic health records were not available. The benefits of automating access to community pharmacy records may be greater for hospitals that are still using paper-based processes as we found that 14.5% of patients had at least one illegible drug in their ED chart, highlighting one of the many benefits of electronic documentation of medication histories. Only publicly insured patients were included, and this subpopulation may be more vulnerable as it includes both older patients and those receiving social assistance. We did not have a definitive 'gold standard' of the current medication list by which the accuracy of the ED list, or the additional drugs identified from community pharmacies could be judged. Moreover, as drug doses and routes were rarely recorded in the chart, we probably underestimated discrepancies related to dose and route.

Conclusion {#s6}
==========

In summary, we found community pharmacy dispensed medication records identified a substantial number of additional medications that were not noted in the ED chart, particularly for the most vulnerable patients. There is potential to gain greater safety and efficiency within hospital ED with automated access to these pharmacy records.
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